lusutrombopag (Mulpleta)

From Aaushi
Jump to navigation Jump to search
[1][2]

Indications

Contraindications

Dosage

  • 3 mg PO QD with or without food for 7 days

Tablets: 3 mg

Adverse effects

Mechanism of action

More general terms

References

  1. ↑ Jump up to: 1.0 1.1 1.2 FDA Approved Drugs. July 31, 2018 FDA approves lusutrombopag for thrombocytopenia in adults with chronic liver disease. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm615348.htm
  2. ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION MULPLETA<TM> (lusutrombopag tablets) for oral use https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210923s000lbl.pdf

Database

Retrieved from "https://aaushi.info/w/index.php?title=A55489&oldid=1027399"